Advertisement
CLDX vs RAPP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Buy and RAPP is a Hold.
CLDX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CLDX turned positive on October 19, 2026. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLDX as a result. In 65 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +3.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 205 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 57 cases where CLDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for CLDX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.283) is normal, around the industry mean (3.498). P/E Ratio (-6.867) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RAPP sees its Stochastic Oscillator ascends from oversold territory
On November 03, 2026, the Stochastic Oscillator for RAPP moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 28 instances where the indicator left the oversold zone. In 26 of the 28 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RAPP's RSI Oscillator exited the oversold zone, 4 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for RAPP just turned positive on October 19, 2026. Looking at past instances where RAPP's MACD turned positive, the stock continued to rise in 26 of 29 cases over the following month. The odds of a continued upward trend are 90%.
Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where RAPP advanced for three days, in 124 of 140 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
RAPP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RAPP as a result. In 39 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RAPP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for RAPP entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.773) is normal, around the industry mean (3.498). P/E Ratio (-8.066) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (92.593) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. RAPP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RAPP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CLDX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 59 | |
P/E GROWTH RATING 1..100 | 26 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CLDX | RAPP | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 74% | 4 days ago 67% |
| Stochastic ODDS (%) | 4 days ago 82% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 76% | 4 days ago 81% |
| MACD ODDS (%) | 4 days ago 85% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 83% | 4 days ago 82% |
| TrendMonth ODDS (%) | 4 days ago 80% | 4 days ago 86% |
| Advances ODDS (%) | 6 days ago 77% | 6 days ago 89% |
| Declines ODDS (%) | 19 days ago 78% | 15 days ago 77% |
| BollingerBands ODDS (%) | 4 days ago 84% | 4 days ago 83% |
| Aroon ODDS (%) | 4 days ago 78% | 4 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLDX’s FA Score shows that 1 FA rating(s) are green while RAPP’s FA Score has 2 green FA rating(s).
- CLDX’s FA Score: 1 green, 4 red.
- RAPP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLDX’s TA Score shows that 5 TA indicator(s) are bullish while RAPP’s TA Score has 5 bullish TA indicator(s).
- CLDX’s TA Score: 5 bullish, 3 bearish.
- RAPP’s TA Score: 5 bullish, 3 bearish.
Price Growth
CLDX (@Biotechnology) experienced а -0.76% price change this week, while RAPP (@Biotechnology) price change was -2.44% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
CLDX is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RAPP and
Correlation & Price change
A.I.dvisor indicates that over the last year, RAPP has been loosely correlated with BCAX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RAPP jumps, then BCAX could also see price increases.
| Ticker / NAME | Correlation To RAPP | 1D Price Change % | ||
|---|---|---|---|---|
| RAPP | 100% | +3.04% | ||
| BCAX - RAPP | 52% Loosely correlated | +5.62% | ||
| STOK - RAPP | 43% Loosely correlated | +1.80% | ||
| LXEO - RAPP | 43% Loosely correlated | -0.52% | ||
| CLDX - RAPP | 42% Loosely correlated | +5.66% | ||
| TRVI - RAPP | 41% Loosely correlated | +11.87% | ||
More | ||||